Epidemiology of female breast cancer

Breast Cancer

Volumn , Issue , 2010, Pages 1-12

  Duffy, Stephen W ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84926088888     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511676314.004     Document Type: Chapter

References (48)

1. Lane-Claypon JE. A Further Report on Cancer of the Breast, with Special Reference to its Antecedent Conditions. Reports on Public Health and Medical Subjects No. 32. London: Ministry of Health, 1926.
2. Cho E, Chen WY, Hunter DJ, et al. Red meat intake and risk of breast cancer among premenopausal women. Arch Intern Med 2006; 166: 2253-9.
3. MacMahon B, Cole P, Lin TM. Age at first birth and breast cancer risk. Bull WHO 1970; 43: 209-21.
4. Lowe CR, MacMahon B. Breast cancer and reproductive history of women in South Wales. Lancet 1970; i: 153-6.
5. Mirra P, Cole P, MacMahon B. Breast cancer in an area of high parity: São Paulo, Brazil. Cancer Res 1971; 31: 77-83.
6. Ravnihar B, MacMahon, Lindtner J. Epidemiologic features of breast cancer in Slovenia 1965-1967. Eur J Cancer 1971; 7: 295-306.
7. Collaborative Group on Hormonal Factors in Breast Cancer. Alcohol, tobacco and breast cancer-collaborative reanalysis of individual data from 53 epidemiological studies, including 58515 women with breast cancer and 95067 women without the disease. Br J Cancer 2002; 87: 1234-45.
8. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy-collaborative reanalysis of individual data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet 1997; 350: 1047-59.
9. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception 1996; 54 (Suppl 3): S1-106.
10. Dumitrescu RG, Cotarla I. Understanding breast cancer risk-where do we stand in 2005? J Cell Mol Med 2005; 9: 208-21.
11. McPherson K, Steel CN, Dixon JM. Breast cancer-epidemiology, risk factors and genetics. Br Med J 2000; 321: 624-8.
12. Lilienfeld AM. The relationship of cancer of the female breast to artificial menopause and martal status. Cancer 1956; 9: 927-34.
13. Lilienfeld AM, Johnson EA. The age distribution in female breast and genital cancers. Cancer 1955; 8: 875-82.
14. Miki Y, Swensen J, Shattuck-Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266: 66-71.
15. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92.
16. Schwartz GF, Hughes KS, Lynch HT, et al. Proceedings of the international consensus conference on breast cancer risk, genetics and risk management, April 2007. Cancer 2008; 113: 2627-37.
17. Vatten LJ, Solvoll K, Løken EB. Frequency of meat and fish intake and risk of breast cancer in a prospective study of 14,500 Norwegian women. Int J Cancer 1990; 46: 12-5.
18. Lee HP, Gourley L, Duffy SW, et al. Dietary effects on breast cancer risk in Singapore. Lancet 1991; 337: 1197-1200.
19. Peeters PH, Keinan-Boker L, van der Schouw YT, et al. Phytoestrogens and breast cancer risk. Review of the epidemiological evidence. Breast Cancer Res Treat 2003; 77: 171-83.
20. McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2006; 15: 1159-69.
21. Boyd N, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007; 356: 227-36.
22. Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296-300.
23. Cuzick J, Forbes J, Edwards R, et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 2002; 360: 817-24.
24. Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther 2008; 8: 1377-85.
25. de Waard F. Breast cancer incidence and nutritional status with particular reference to body weight and height. Cancer Res 1975; 35: 3351-6.
26. Harvie M, Howell A, Vierkant RA, et al. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2005; 14: 656-61.
27. Friedenreich CM. Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev 2001; 10: 15-32.
28. Willett WC. Diet and breast cancer. J Intern Med 2001; 249: 395-411.
29. Keinan-Boker L, van der Schouw YT, Grobbee DE, et al. Dietary phytoestrogens and breast cancer risk. Am J Clin Nutr 2004; 79: 282-8.
30. Yamamoto S, Sobue T, Kobayashi M, et al. Soy, isoflavones and breast cancer risk in Japan. J Natl Cancer Inst 2003; 92: 906-13.
31. Iwasaki M, Inoue M, Otani T, et al. Plasma isoflavone level and subsequent risk of breast cancer among Japanese women: a nested case-control study from the Japan Public Health Center-based prospective study group. J Clin Oncol 2008; 26: 1677-83.
32. Wu AH, Yu MC, Tseng CC, et al. Epidemiology of soy exposures and breast cancer risk. Br J Cancer 2008; 98: 9-14.
33. Lagerros YT, Hsieh SF, Hsieh CC. Physical activity in adolescence and young adulthood and breast cancer risk: a quantitative review. Eur J Cancer Prev 2004; 13: 5-12.
34. Friedenreich CM, Cust AE. Physical activity and breast cancer risk: impact of timing, type and dose of activity and population subgroup effects. Br J Sports Med 2008; 42: 636-47.
35. Monninkhof EM, Elias SG, Vlems FA, et al. Physical activity and breast cancer: a systematic review. Epidemiology 2007; 18: 137-57.
36. Pharoah PDP, Day NE, Duffy SW, et al. Family history and the risk of breast cancer: a systematic review and meta-analysis. Int J Cancer 1997; 71: 800-9.
37. Collaborative Group on Hormonal Factors in Breast Cancer. Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 2001; 358: 1389-99.
38. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007; 447: 1087-93.
39. Leach MO, Boggis CR, Dixon AK, et al. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet 2005; 365: 1769-78.
40. FH01 management committee, steering committee and collaborators. The challenge of evaluating annual mammography screening for young women with a family history of breast cancer. J Med Screen 2006; 13: 177-182.
41. Wolfe JN. Risk for breast cancer development determined by mammographic pattern. Cancer 1976; 37: 2486-92.
42. Gram IT, Funkhouser E, Tabar L. The Tabár classification of mammographic parenchymal patterns. Eur J Radiol 1997; 24: 131-6.
43. Bassett LW, Feig SA, Jackson VP, et al. American College of Radiology (ACR) Breast Imaging Reporting and Data System (BIRADSTM). 3rd ed. Reston VA: American College of Radiology, 1998.
44. Haars G, van Noord PA, van Gils CH, et al. Measurements of breast density: no ratio for a ratio. Cancer Epidemiol Biomarkers Prev 2005; 14: 2634-40.
45. Boyd NF, Rommens JM, Vogt K, et al. Mammographic density as an intermediate phenotype for breast cancer. Lancet Oncol 2005; 6: 798-808.
46. Cuzick J, Warwick J, Pinney E, et al. Effect of tamoxifen on breast density in women at increased risk of breast cancer. J Natl Cancer Inst 2004; 96: 621-8.
47. Bjurstam N, Björneld L, Warwick J, et al. The Gothenburg mammographic screening trial. Cancer 2003; 97: 2387-96.
48. Duffy SW, Tabar L, Smith RA, et al. Risk of breast cancer and risks with breast cancer: the relationship of histologic type with epidemiology, disease progression and survival. Sem Breast Dis 1999; 2: 292-300.